Liafensine - Denovo Biopharma
Alternative Names: BMS-820836; DB 104Latest Information Update: 16 Oct 2024
At a glance
- Originator AMRI
- Developer Bristol-Myers Squibb; Denovo Biopharma
- Class Antidepressants; Isoquinolines; Naphthalenes; Pyridazines; Small molecules; Tetrahydroisoquinolines
- Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Depressive disorders
- Preclinical Major depressive disorder
Most Recent Events
- 09 Oct 2024 Liafensine - Denovo Biopharma receives Fast Track designation for Depressive disorders [PO] (Treatment-resistant) in USA
- 03 Apr 2024 Liafensine is available for market licensing
- 03 Apr 2024 Efficacy and adverse event data from the phase IIb ENLIGHTEN trial in Major depressive disorder released by Denovo Biopharma